FDA Approves High-Dose Wegovy — Novo Nordisk Launches 7.2mg Semaglutide
By FieldPulse Staff · March 19, 2026
Tags: launch, field, strategy
FDA clears semaglutide 7.2mg on March 19 with 20.7% average weight loss data. Novo plans April launch, adding a third SKU to an already crowded GLP-1 portfolio.
The FDA approved Wegovy HD (semaglutide 7.2 mg injection) on March 19, 2026, clearing a higher-dose version of Novo Nordisk's blockbuster weight-loss drug for adults with obesity or overweight with at least one weight-related condition.
The new dose delivered a mean 20.7% body weight reduction in Phase 3 trials, with approximately 31% of participants losing 25% or more of their body weight — a benchmark that has become the gold standard in the obesity category.
The approval notably came through the FDA Commissioner's new National Priority Voucher pilot program, enabling an accelerated review timeline.
Novo Nordisk announced plans for a U.S.
commercial launch in April 2026.
The expanded Wegovy portfolio now includes the 2.4mg injection, the newly launched oral Wegovy pill (priced at $149–$299/month), and the new 7.2mg HD formulation — giving the field force three distinct SKUs to detail simultaneously.
For reps already navigating positioning complexity between injectable and oral semaglutide, the HD launch adds another layer heading into Q2.